Sarepta Therapeutics Seeks Full FDA Approval for DMD Therapies Amondys 45 and Vyondys 53

Sarepta Therapeutics (SRPT) has announced plans to submit filings to the U.S. Food and Drug Administration (FDA) to convert the accelerated approvals of its Duchenne Muscular Dystrophy (DMD) treatments into full approvals. The therapies involved, Amondys 45 and Vyondys 53, are currently marketed under the FDA's accelerated pathway. Despite missing a primary endpoint in a recent confirmatory study, the company intends to leverage new supplemental data to support its application for permanent regulatory status. This move represents a significant milestone as the company seeks to solidify the market position of its specialized therapies. Investors are closely monitoring the FDA's response, as full approval would mitigate risks associated with the temporary nature of accelerated status. While the missed trial endpoint introduces some uncertainty, the company remains confident in the overall clinical benefit demonstrated by the treatments.